NICE changes stance on Lilly’s breast cancer dug VerzeniosAfter rejecting Eli Lilly’s Verzenios for breast cancer therapy earlier this year, NICE has relented, recommending the drug Share XNICE changes stance on Lilly’s breast cancer dug Verzenioshttps://pharmaphorum.com/news/nice-changes-stance-on-lillys-breast-cancer-dug-verzenio/
Ibrance trial failure dashes Pfizer’s growth hopes for the drugPfizer already makes big revenues from its breast cancer drug Ibrance, but a late-stage trial failure has set Share XIbrance trial failure dashes Pfizer’s growth hopes for the drughttps://pharmaphorum.com/news/ibrance-trial-failure-dashes-pfizers-growth-hopes-for-the-drug/
Lilly’s Verzenio fails in KRAS-mutated lung cancerLilly’s Verzenio has failed to show benefits in lung cancer patients with a KRAS mutation, denting the company’s Share XLilly’s Verzenio fails in KRAS-mutated lung cancerhttps://pharmaphorum.com/news/verzenio-fails-lung-cancer/
